MapLight Therapeutics
MPLT
74 hedge funds and large institutions have $405M invested in MapLight Therapeutics in 2025 Q4 according to their latest regulatory filings, with 74 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
50.84% more ownership
Funds ownership: 0% → 50.84% (+51%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$61.8M |
| 2 |
FIS
FCPM III Services
Naarden,
Netherlands
|
+$54.1M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$46.9M |
| 4 |
Goldman Sachs
New York
|
+$32.5M |
| 5 |
BlackRock
New York
|
+$18.4M |
Top Sellers
MPLT Hedge Fund Activity: Q4 2025 in Review
74 of the 8,286 institutional investors tracked by Wall St. Rank reported a position in MapLight Therapeutics (MPLT) for Q4 2025, worth a combined $405M.
Buyers outnumbered sellers: 74 funds opened new MPLT positions and 0 closed out — a net gain of 74 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $61.8M.
- 74 institutional investors held MapLight Therapeutics (MPLT) as of Q4 2025, up from 0 in Q3 2025.
- Funds reported $405M of MapLight Therapeutics stock for Q4 2025.
- 74 funds opened new MapLight Therapeutics positions in Q4 2025 and 0 closed out, a net change of +74 holders.
- The largest MapLight Therapeutics buyer in Q4 2025 was Novo Holdings A/S, an estimated $61.8M added.
Based on aggregated 13F filings for Q4 2025.